DOP2016000120A - Nuevos inhibidores de dgat2 - Google Patents

Nuevos inhibidores de dgat2

Info

Publication number
DOP2016000120A
DOP2016000120A DO2016000120A DO2016000120A DOP2016000120A DO P2016000120 A DOP2016000120 A DO P2016000120A DO 2016000120 A DO2016000120 A DO 2016000120A DO 2016000120 A DO2016000120 A DO 2016000120A DO P2016000120 A DOP2016000120 A DO P2016000120A
Authority
DO
Dominican Republic
Prior art keywords
new
dgat2 inhibitors
dgat2
inhibitors
compounds
Prior art date
Application number
DO2016000120A
Other languages
English (en)
Inventor
Nicholas Paul Camp
Manisha Naik
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016867&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2016000120(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2016000120A publication Critical patent/DOP2016000120A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS DE LA SIGUIENTE FÓRMULA: DONDE R ES H O -CH3; MÉTODOS DE TRATAMIENTO DE PACIENTES PARA HIPERTRIGLICERIDEMIA Y ENFERMEDADES CARDIOVASCULARES QUE INCLUYEN DISLIPIDEMIA Y ATEROSCLEROSIS, Y PROCESOS PARA PREPARAR LOS COMPUESTOS.
DO2016000120A 2013-11-25 2016-05-24 Nuevos inhibidores de dgat2 DOP2016000120A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361908339P 2013-11-25 2013-11-25

Publications (1)

Publication Number Publication Date
DOP2016000120A true DOP2016000120A (es) 2016-06-15

Family

ID=52016867

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000120A DOP2016000120A (es) 2013-11-25 2016-05-24 Nuevos inhibidores de dgat2

Country Status (24)

Country Link
US (1) US9073901B2 (es)
EP (1) EP3074381B1 (es)
JP (1) JP6155395B2 (es)
KR (1) KR20160072252A (es)
CN (1) CN105764889B (es)
AP (1) AP2016009230A0 (es)
AR (1) AR098394A1 (es)
AU (1) AU2014353109B2 (es)
CA (1) CA2928468A1 (es)
CL (1) CL2016001172A1 (es)
CR (1) CR20160216A (es)
DO (1) DOP2016000120A (es)
EA (1) EA201690847A1 (es)
ES (1) ES2695302T3 (es)
HK (1) HK1223367A1 (es)
IL (1) IL245245A0 (es)
MA (1) MA39048B1 (es)
MX (1) MX2016006665A (es)
NZ (1) NZ719444A (es)
PE (1) PE20161099A1 (es)
PH (1) PH12016500963A1 (es)
TN (1) TN2016000146A1 (es)
TW (1) TW201609668A (es)
WO (1) WO2015077299A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982267C (en) * 2015-05-20 2019-11-12 Eli Lilly And Company Novel dgat2 inhibitors
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
WO2021236401A1 (en) 2020-05-18 2021-11-25 Merck Sharp & Dohme Corp. Novel diacylglyceride o-acyltransferase 2 inhibitors
MX2023003842A (es) 2020-10-08 2023-04-14 Merck Sharp & Dohme Llc Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2.
US20240092756A1 (en) 2020-11-20 2024-03-21 2692372 Ontario, Inc. Methods and composition for kras modifications
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455815A4 (en) 2001-12-19 2006-11-02 Millennium Pharm Inc MEMBERS OF THE DIACYLGLYCEROL-ACYLTRANSFERASES FAMILY 2 (DGAT2) AND USES THEREOF
US20050288213A1 (en) 2002-07-18 2005-12-29 Macneil Douglas J Combination therapy for the treatment of obesity
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
DK1756084T3 (da) * 2004-06-04 2009-03-23 Arena Pharm Inc Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
EP1807102A2 (en) 2004-10-29 2007-07-18 Merck & Co., Inc. Compositions and methods for the treatment of obesity and sexual dysfunction
JP5566880B2 (ja) 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤としての４，６−二置換アミノピリミジン誘導体
JP2013515085A (ja) 2009-12-22 2013-05-02 ジ・アドミニストレイターズ・オブ・ザ・チユレーン・エデユケーシヨナル・フアンド 肥満症および糖尿病を治療するための組成物および方法
WO2011078102A1 (ja) * 2009-12-22 2011-06-30 第一三共株式会社 新規フェノキシピリミジン誘導体
US20130079345A1 (en) 2010-03-22 2013-03-28 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
AU2012223720A1 (en) * 2011-03-03 2013-09-26 Vanderbilt University 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
EP2561867A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9 inhibitors in the treatment of midline carcinoma
EP2562265A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Susceptibility to selective CDK9 inhibitors
CA2869587A1 (en) 2012-04-06 2013-10-10 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors

Also Published As

Publication number Publication date
EP3074381A1 (en) 2016-10-05
US9073901B2 (en) 2015-07-07
CL2016001172A1 (es) 2016-12-09
MA39048B1 (fr) 2018-04-30
AR098394A1 (es) 2016-05-26
CN105764889B (zh) 2018-01-02
US20150148358A1 (en) 2015-05-28
TW201609668A (zh) 2016-03-16
CA2928468A1 (en) 2015-05-28
IL245245A0 (en) 2016-06-30
TN2016000146A1 (en) 2017-10-06
KR20160072252A (ko) 2016-06-22
NZ719444A (en) 2017-12-22
JP6155395B2 (ja) 2017-06-28
WO2015077299A1 (en) 2015-05-28
CN105764889A (zh) 2016-07-13
PH12016500963A1 (en) 2016-06-20
EA201690847A1 (ru) 2016-09-30
AP2016009230A0 (en) 2016-05-31
AU2014353109B2 (en) 2017-02-02
JP2016539115A (ja) 2016-12-15
EP3074381B1 (en) 2018-07-04
MX2016006665A (es) 2016-07-26
MA39048A1 (fr) 2017-05-31
ES2695302T3 (es) 2019-01-03
PE20161099A1 (es) 2016-10-22
AU2014353109A1 (en) 2016-05-12
CR20160216A (es) 2016-06-27
HK1223367A1 (zh) 2017-07-28

Similar Documents

Publication Publication Date Title
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
DOP2016000120A (es) Nuevos inhibidores de dgat2
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201691135A1 (ru) Новые ингибиторы глутаминазы
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EA201691582A1 (ru) Новые фармацевтические препараты
CO6761389A2 (es) Inhibidores de nampt y rock
CL2017001046A1 (es) Inhibidoes del bromodominio
DOP2014000253A (es) Inhibidores del nampt
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201690844A1 (ru) Ингибиторы gsk-3
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
UY37017A (es) Inhibidores aza-bencimidazol de pad4
NI201600021A (es) Inhibidores de rorc2 heterobicicloarilo y sus métodos de uso
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
EA201690227A1 (ru) Азаиндольные соединения, их получение и способы их применения
EA201790484A1 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2